Prior treatment with oxaliplatin-containing regimens and higher total bilirubin levels are risk factors for neutropenia and febrile neutropenia in patients with gastric or esophagogastric junction cancer receiving weekly paclitaxel and ramucirumab therapy: a single center retrospective study

Abstract Background Weekly paclitaxel + ramucirumab (wPTX + RAM) therapy is recommended as the standard second-line chemotherapy regimen for unresectable advanced/recurrent gastric cancer (GC) or esophagogastric junction cancer. Recent subgroup analysis of the RAINBOW trial revealed a higher frequen...

Полное описание

Библиографические подробности
Главные авторы: Katsuhiko Nara, Takehito Yamamoto, Hiroharu Yamashita, Koichi Yagi, Tappei Takada, Yasuyuki Seto, Hiroshi Suzuki
Формат: Статья
Язык:English
Опубликовано: BMC 2023-10-01
Серии:BMC Cancer
Предметы:
Online-ссылка:https://doi.org/10.1186/s12885-023-11469-y

Схожие документы